Bioventus Inc. Stock Price, News & Analysis

Bioventus (Nasdaq: BVS) announced the filing of a Form 12b-25 for late submission of its quarterly report for the period ending October 1, 2022. Following a decline in market capitalization after its Q3 earnings release, Bioventus is reviewing potential non-cash impairment charges, estimating between $185 million and $205 million. The company is also addressing a revised invoice related to rebate claims that may adversely influence its Q3 financial results and revenue guidance. Despite these challenges, Bioventus does not expect changes to its adjusted EBITDA guidance for 2022.

Bioventus reported Q3 2022 net sales of $137.1 million, reflecting a 25.9% year-over-year increase, with net income of $3.2 million compared to a net loss of $2.3 million in Q3 2021. Adjusted EBITDA rose to $22.7 million. However, the company reduced its full-year sales guidance to $527-$532 million from $547.5-$562.5 million, citing temporary reimbursement issues and the discontinuation of the MOTYS development. Cash and cash equivalents decreased to $34.4 million alongside increased debt obligations of $424.4 million.

Bioventus (BVS) will announce its Q3 fiscal results on November 8, 2022, before market opening. A conference call is scheduled for 8:30 a.m. ET on the same day to discuss the results and provide a business update. Interested participants can join by dialing 1-833-636-0497 domestically or +1-412-902-4241 internationally. A live webcast and materials will be accessible through the Investor Relations section of Bioventus' website, with archived availability until November 7, 2023.

Bioventus (Nasdaq: BVS) has announced the full launch of BoneScalpel® Access™, a new product for minimally invasive spine surgery, at the North American Spine Society (NASS) meeting in Chicago from October 12 to 15, 2022. The BoneScalpel Access features ultrasonic cutting technology and works in conjunction with OSTEOAMP® bone grafts. This launch reflects Bioventus' commitment to expanding its procedural solutions portfolio and aims to enhance surgical outcomes. The product will be available in the U.S. starting on October 17, 2022.

Bioventus (Nasdaq: BVS) announced that CFO Mark Singleton will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 14, 2022, at 11:10 a.m. ET. The event will be accessible via a live webcast on the company's website, with a replay available afterward. Bioventus focuses on innovative healing solutions, offering clinically proven, cost-effective products that support recovery and active living. The company emphasizes high-quality standards and evidence-based practices to assist healthcare professionals globally.

Bioventus Inc. (Nasdaq: BVS) reported strong Q2 2022 results with net sales reaching $140.3 million, up 27.8% year-over-year. The net loss improved to ($8.0 million) from ($10.8 million) the previous year. Adjusted EBITDA stood at $22.9 million, an increase from $19.9 million in Q2 2021. However, loss per share slightly worsened at ($0.11), compared to ($0.10) a year ago. The company provided updated full-year guidance, anticipating net sales of $547.5 million to $562.5 million. Bioventus also discontinued the development of MOTYS to focus on integration following its recent CartiHeal acquisition.

Bioventus Inc. (Nasdaq: BVS) announced FDA clearance for the neXus® SonaStar Elite® handpiece, expanding its neurosurgery ablation capabilities. This new handpiece, part of the neXus Ultrasonic Surgical Aspirator System, enhances control and versatility in soft and hard tissue removal, including tumors. The SonaStar Elite can perform procedures on both benign and malignant brain and spinal tumors. Bioventus emphasizes its commitment to developing innovative, market-leading technologies for improved surgical outcomes.

Bioventus Inc. (NASDAQ: BVS) is set to report its financial results for the second quarter of fiscal year 2022 on August 11, 2022, before the market opens. Management will host a conference call at 8:30 a.m. Eastern Time to discuss results and provide a business update. Investors can participate by calling 1-833-636-0497 domestically or +1-412-902-4241 internationally. A live webcast will be available in the Investor Relations section of the company's website and will be archived for replay until August 10, 2023.

Bioventus (BVS) has successfully completed its acquisition of CartiHeal, enhancing its portfolio in the treatment of osteoarthritis and knee defects. This strategic move positions Bioventus to leverage CartiHeal's Agili-C implant, which has shown superiority in clinical trials over current treatments like microfracture and debridement. With approximately 650,000 U.S. patients undergoing such procedures annually, the acquisition aims to delay total knee replacements and supports Bioventus’ growth goals of sustained double-digit revenue increases. Adjusted earnings per share guidance will be provided in the upcoming Q2 earnings call.